Delving into the Latest Updates on Tislelizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Tirelizumab, Tiselizumab, Tislelizumab (USAN/INN)

+ [8]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesDigestive System Disorders+ [10]

Active Indication

Esophageal CarcinomaPD-L1 positive Esophageal Squamous Cell CarcinomaLocally Advanced Gastric Adenocarcinoma+ [117]

Inactive Indication

Advanced biliary tract cancerAdvanced Hepatocellular CarcinomaAdvanced Lung Non-Small Cell Squamous Carcinoma+ [39]

Originator Organization

BeOne Medicines Ltd.

Active Organization

BeOne Medicines Ltd.

Glenmark Pharmaceuticals Ltd.

Novartis AG

+ [14]

Inactive Organization

Asieris Pharmaceuticals Co., Ltd.

Celgene Corp.

HUTCHMED (China) Ltd.

+ [2]

License Organization

Glenmark Specialty SA

BeOne Medicines Ltd.

Hutchison MediPharma Ltd.

+ [13]

Drug Highest PhaseApproved

First Approval Date

China (26 Dec 2019),

Hodgkin's Lymphoma

RegulationOrphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan), Priority Review (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 577079733L

Source: *****

Sequence Code 616719194H

Source: *****

This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as BGB-A317) for refractory solid tumors in approximately 72 patients with centrally confirmed T cell inflamed GEP score ≥ 0.857, who have not been previously exposed to immunotherapy.
All patients must provide a tumor specimen for T cell inflamed GEP assessment. Archived tissue slide collected within 2 years from the first dose of study drug must be provided.
This study will include a Screening Period, a Treatment Period, and a Follow-Up Period. All patients will complete up to 28 days of screening. During the Treatment Period, patients will receive tislelizumab 200 mg fixed dose once every 3 weeks by intravenous (IV) administration until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
After treatment discontinuation, patients will be follow-up for disease progression and survival status until death, withdrawal of consent, or study closure, whichever occurs first.
The end of study will be the timepoint when the final data for the study were collected. Additionally, the Investigator Sponsor has the right to terminate this study at any time.

Start Date01 Aug 2026

Sponsor / Collaborator

Samsung Medical Center

NCT07686926

/ Not yet recruitingPhase 2IIT

Becotatug Vedotin Combined With Tislelizumab and Low-Dose Lenvatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Failed First-Line Therapy: A Phase II Exploratory Study

Immunotherapy combined with chemotherapy has become the first-line standard of care for advanced esophageal squamous cell carcinoma (ESCC), significantly improving patient survival. However, with the widespread adoption of first-line immunotherapy, most patients eventually develop immune resistance. After first-line treatment failure, there is currently no established standard effective therapy for second-line ESCC. Therefore, more effective and safer treatment options are urgently needed for second-line advanced ESCC.
This is a prospective, single-arm, single-center, open-label, Phase II clinical study aiming to evaluate the efficacy and safety of Becotatug Vedotin combined with Tislelizumab and low-dose Lenvatinib in patients with advanced ESCC who have failed first-line therapy. Eligible patients will receive Becotatug Vedotin combined with Tislelizumab and low-dose Lenvatinib. The primary endpoint is objective response rate (ORR) assessed per RECIST v1.1. Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), duration of response (DOR), overall survival (OS), and safety.

Start Date01 Aug 2026

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

100 Clinical Results associated with Tislelizumab

Login to view more data

100 Translational Medicine associated with Tislelizumab

Login to view more data

100 Patents (Medical) associated with Tislelizumab

Login to view more data

782

Literatures (Medical) associated with Tislelizumab

01 Aug 2026·MEDICINA CLINICA

A case of thrombotic microangiopathy during tislelizumab therapy for lung cancer

Letter

Author: Zou, Yumeng ; Zhang, Nannan

15 Jul 2026·INTERNATIONAL JOURNAL OF CANCER

Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases

Article

Author: Yuqi Jiang ; Changyu Li ; Juncheng Wan ; Yongjie Zhou ; Chaoqiao Jin ; Xudong Qu ; Caihong Yu

Abstract:

This study evaluated the efficacy and safety of bronchial arterial infusion (BAI) chemotherapy combined with transarterial chemoembolization (TACE) plus systemic therapy in hepatocellular carcinoma (HCC) patients with lung metastases. This study retrospectively analyzed 54 HCC patients with lung metastases who underwent TACE combined with systemic therapy and/or BAI chemotherapy, at initial diagnosis from January 2018 to June 2023. Systemic therapy included targeted agents (apatinib, lenvatinib, and regorafenib, or bevacizumab) and programmed cell death protein 1 (PD‐1) inhibitors (sintilimab, camrelizumab, and tislelizumab). During follow‐up, treatment‐related adverse events were recorded. Progression‐free survival (PFS) was assessed separately for lung metastases and intrahepatic lesions, along with overall survival (OS). Fifty‐four eligible patients with HCC were enrolled, including 32 in the BAI plus TACE and systemic therapy group (BTS group) and 22 in the TACE plus systemic therapy group (TS group). At 3 months post‐treatment, the BTS group showed significantly higher objective response rate of lung metastatic lesions (50.0% vs. 22.7%, p = .043) and disease control rate (DCR) (93.7% vs. 68.2%, p = .013) than the TS group. By study end, DCR remained higher in the BTS group (84.4% vs. 54.5%, p = .016). Median PFS of lung metastatic lesions was 7.1 versus 3.3 months ( p = .004), and median OS was 13.9 versus 7.6 months ( p = .009), both favoring the BTS group. The combination of BAI, TACE, and systemic therapy achieved favorable therapeutic outcomes and acceptable safety in patients with HCC with lung metastases.

15 Jun 2026·CLINICAL CANCER RESEARCH

The Efficacy and Safety of Tislelizumab plus Anlotinib as First-line Treatment in Advanced Pulmonary Sarcomatoid Carcinoma: A Single-Arm Phase II Trial

Article

Author: Zhang, Xiaoqiang ; Cai, Jing ; Zeng, Zhimin ; Huang, Wenqian ; Zheng, Yue’e ; Liu, Chenyi ; Zeng, Fujuan ; Huang, Long ; Chen, Ziye ; Liu, Anwen ; Xiong, Le

Abstract:

Purpose::

Pulmonary sarcomatoid carcinoma (PSC) is a highly aggressive and poorly differentiated subtype of non–small cell lung cancer (NSCLC) associated with a poor prognosis. We conducted a prospective, single-arm, phase II trial to evaluate the efficacy and safety of tislelizumab in combination with anlotinib as first-line therapy in patients with advanced PSC.

Patients and Methods::

Eligible patients with advanced PSC without EGFR or ALK mutations received tislelizumab plus anlotinib as first-line treatment until disease progression or unacceptable toxicities. The primary endpoint was the objective response rate (ORR) assessed per RECIST version 1.1. Secondary endpoints included the disease control rate (DCR), duration of response, progression-free survival (PFS), overall survival (OS), and safety.

Results::

Between August 2021 and June 2025, a total of 29 patients were enrolled, with a median age of 71 years (range: 39–79). Two patients (6.90%) achieved a complete response, and 14 (48.28%) achieved a partial response, yielding an ORR of 55.17% [95% confidence interval (CI), 35.69%–73.55%]. The DCR was 96.55% (95% CI, 82.24%–99.91%). After a median follow-up duration of 16.73 months, the median PFS was 9.40 months (95% CI, 3.67–13.30 months), and the median OS was 14.37 months (95% CI, 9.03–17.50 months). The most common treatment-related adverse events (TRAE) were hyperuricemia and maculopapular rash. Grade 3 to 4 TRAEs occurred in eight patients (27.59%), with no treatment-related deaths reported.

Conclusions::

The combination of tislelizumab and anlotinib demonstrated promising antitumor activity with a manageable safety profile as first-line therapy in patients with advanced PSC.

614

News (Medical) associated with Tislelizumab

17 Jun 2026

·www.biospace.com

Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B

Getty Images/ seamartini Jazz Pharmaceuticals is diversifying its oncology strategy, orchestrating a new antibody deal with AbCellera that offers $56 million upfront, plus $792 million in biobucks for each of the three initial programs. Jazz Pharmaceuticals is banding together with AbCellera, paying $56 million cash and offering up to some $2.46 billion in total to develop next-generation T cell engagers for hard-to-treat cancers. The collaboration features AbCellera’s multispecific T cell engager (TCE) platform, science that will be fine-tuned in hopes of creating candidates for multiple gastrointestinal (GI) cancers and other solid tumors for which current treatments fall flat. AbCellera will perform discovery and early-stage research for two initial programs, with plans to start a third discovery program in the next year, according to a Wednesday release . For each program, Jazz can opt in for a fee that would grant the biopharma exclusive rights to the candidate. Should Jazz exercise its option, AbCellera could be in line to receive up to $792 million in milestone payments per program, plus tiered royalties. For the work on the first two programs, Canada-based AbCellera will receive $56 million upfront. The biotech will get another $28 million when work on the third program begins. Under the terms of the deal, the partners can also tack on two additional programs, though potential payments for these were not disclosed. “This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” Jazz Chief Scientific Officer Josh Allen said in the release. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies for GI cancers and other solid tumors into clinical development and to develop meaningful innovation for patients.” For Truist analysts, the move underscores Jazz’s growing focus on GI cancers. The expansion builds off Ziihera, a bispecific HER2-directed antibody that has secured priority review for a label expansion into first-line HER2+ gastroesophageal adenocarcinoma, with an FDA decision expected on or by Aug. 25. Stomach cancer Jazz’s Ziihera Shows ‘Practice-Changing’ Efficacy in Stomach Cancer Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall survival signals ever reported in a type of gastroesophageal cancer. January 7, 2026 · 2 min read · Tristan Manalac Read more “We view continued external BD as reinforcing the balanced-portfolio thesis as JAZZ’s onco lean-in and diversification effort has been lively,” Truist wrote in a Wednesday morning note. “While this deal brings additional oncology flavor to the JAZZ platform, we continue to anticipate recurring BD activity in rare disease spaces,” the analysts added. The move also comes directly after Jazz’s alkylating drug Zepzelca failed to improve overall survival for patients with relapsed metastatic small cell lung cancer in a Phase 3 trial last week. The study brings a second line expansion into question, Truist analysts said in a June 12 note, adding, however, that they see the first-line indication as the primary growth driver. Now Jazz will have access to AbCellera’s platform, which includes proprietary panels of CD3-binding antibodies and rapid testing systems to help design multispecific drugs. “Building on years of experience in TCEs, we are pleased to partner with Jazz Pharmaceuticals to leverage AbCellera’s differentiated TCE platform to bring forward novel cancer treatments for GI cancers and other solid tumors,” AbCellera founder and CEO Carl Hansen said in a prepared statement. AbCellera has also teamed up with AbbVie, last year expanding an existing deal to include TCEs for oncology.

Phase 3Priority Review

09 Jun 2026

·allsci.com

BeOne/Huahui advance trispecific antibody against PD-1, CTLA-4, and VEGF-A into the clinic

Beijing-based Huahui Health has initiated a first-in-human trial of HH160, a potential first-in-class trispecific antibody engineered to block PD-1, CTLA-4, and VEGF-A within a single molecule. The trial’s relevance lies in whether simultaneous triple blockade — combining dual checkpoint inhibition with anti-angiogenic activity in one construct — can improve on the toxicity and efficacy profile of combining three separate agents, a question that has grown more pressing as PD-1/CTLA-4 combinations become standard of care in several tumor types. BeOne Medicines (Nasdaq: ONC), which agreed in April 2026 to pay USD 20 million upfront for a global exclusive option to license HH160 in a deal valued at up to approximately USD 2.02 billion, is listed as a collaborator and study director. The Phase I study (NCT07623369) follows a two-part sequential design, with Part 1 consisting of dose escalation across patients with advanced solid tumors to establish the maximum tolerated dose, and Part 2 a safety expansion cohort in selected tumor types. The specific tumor types include non-small cell lung cancer (NSCLC), hepatocellular carcinoma, colorectal cancer, and additional indications to be determined by emerging data. HH160 is administered by intravenous infusion every three weeks. The trial is open-label and non-randomized, according to the trial record. Enrollment is planned for approximately 56 participants with eligible tumor types spanning a broad range of solid malignancies, including gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma, renal cell carcinoma, endometrial carcinoma, cervical cancer, ovarian cancer, small cell lung cancer, triple-negative breast cancer, and urothelial carcinoma. Patients with active leptomeningeal disease, uncontrolled brain metastases, or significant bleeding risk are excluded. Primary completion is expected by August 2028. HH160’s hexavalent architecture with silent Fc HH160 was constructed by fusing anti-PD-1 and anti-CTLA-4 nanobodies to the N- and C-termini of the heavy chain of an anti-VEGF-A human IgG1 antibody, forming a symmetrical hexavalent molecule with two binding sites per target, according to a preclinical abstract presented at the AACR Annual Meeting (Cancer Research, 2025). The Fc region is silenced — attenuating effector functions — a design choice that in the checkpoint inhibitor field is generally employed to prevent Fc-mediated depletion of PD-1- or CTLA-4-expressing T cells. The use of nanobody-based domains for the checkpoint arms is mechanistically notable. Nanobodies, derived from single-domain camelid antibody fragments, are substantially smaller than conventional Fab regions, enabling a more compact and potentially more manufacturable multi-specific architecture. The anti-VEGF-A conventional IgG1 backbone provides the structural scaffold. Huahui Health developed HH160 on its proprietary PolyBoost multispecific antibody platform, which the company describes as enabling this type of multi-arm construction. The rationale for combining these three targets rests on complementary mechanisms: PD-1 and CTLA-4 blockade act at distinct stages of the T cell activation cycle, while VEGF-A inhibition addresses the immunosuppressive and pro-angiogenic tumor microenvironment. The most direct clinical-stage comparator is cadonilimab (AK104, Akeso), a PD-1×CTLA-4 bispecific antibody approved in China for cervical cancer, which demonstrated that dual checkpoint blockade in a single molecule is clinically feasible and potentially safer than ipilimumab-based combinations. HH160 adds VEGF-A blockade to this framework, a design also being explored by Akeso with ivonescimab (PD-1×VEGF bispecific), which has reported Phase III data in NSCLC. The BeOne partnership, announced in April 2026, gives BeOne the right to exercise its option following Phase I data readout, positioning the company to potentially integrate HH160 into a broader solid tumor portfolio that already includes the PD-1 inhibitor tislelizumab. The immunogenicity study components built into the Phase I protocol will also be closely watched, given that multi-specific formats with nanobody-derived domains can present distinct immunogenic profiles relative to conventional monoclonal antibodies. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Copyright © 2026. AllSci Corp. All rights reserved.

05 Jun 2026

·www.biospace.com

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC) CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. ( NASDAQ: IBRX ), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized Phase 3 trials in advanced NSCLC and a matched adjusted indirect comparison (MAIC) in BCG unresponsive non-muscle invasive bladder cancer (NMIBC), and collectively evaluate ANKTIVA ® (nogapendekin alfa inbakicept-pmln), the company’s IL-15 receptor agonist immunotherapy designed to activate natural killer (NK) cells, CD4+ and CD8+ T cells, and memory T cells, across multiple solid tumor indications. “ASCO provides an important opportunity to share emerging clinical and translational data that continue to deepen our understanding of how ANKTIVA-based immunotherapy may restore immune function and rescue or reinvigorate the response to checkpoint inhibitors,” said Dr. Patrick Soon-Shiong, Founder, Executive Chairman, and Global Chief Scientific and Medical Officer of ImmunityBio. “ANKTIVA is the first FDA-approved immunotherapy designed to stimulate NK cells, CD4+ and CD8+ T cells, and memory T cells, which are the very immune cells that are depleted in patients with lymphopenia and that are critical to mounting an effective anti-tumor response. Growing long-term survival data across bladder, lung and other solid tumors are beginning to put in focus a compelling hypothesis: that restoring immune competence and addressing lymphopenia may be as a fundamental to cancer care as targeting the tumor itself. These findings reinforce our conviction that the future of immunotherapy lies in activating and amplifying the immune system, not suppressing it.” Presentation highlights include: ASCO 2026 Annual Meeting Poster Presentations - Sunday, May 31st (9am-12pm) Poster Title: Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy Poster Board: 455am Abstract: #TPS8671 Presenter: Andreas Saltos (Affiliation: Moffitt) Poster Title: Efficacy outcomes in first line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT‑2.023 randomized phase 3 study of IL‑15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy Poster Board: 378 Abstract: #8588 Presenter: John Wrangle (Affiliation: MUSC) Online Publication Only Abstract Title: A matched adjusted indirect comparison (MAIC) of NAI+BCG & pembrolizumab in patients with BCG unresponsive NMIBC with CIS ± papillary disease – Will be published on at 5:00 PM EDT on May 21, 2026 About ANKTIVA ® (nogapendekin alfa inbakicept-pmln) The interleukin-15 (IL-15) cytokine plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved in killing cancer cells. By activating NK cells, ANKTIVA ® overcomes the tumor escape phase of clones resistant to T cells and restores memory T cell activity with resultant prolonged duration of complete response. ANKTIVA® is a first-in-class IL-15 receptor agonist IgG1 fusion complex, consisting of an IL-15 mutant (IL-15N72D) fused with an IL-15 receptor alpha, which binds with high affinity to IL-15 receptors on NK, CD4+, and CD8+ T cells. This fusion complex of ANKTIVA ® mimics the natural biological properties of the membrane-bound IL-15 receptor alpha, delivering IL-15 by dendritic cells and driving the activation and proliferation of NK cells with the generation of memory killer T cells that have retained immune memory against these tumor clones. About ImmunityBio ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield ™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 receptor superagonist, ANKTIVA ® (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. For more information, visit ImmunityBio.com and connect with us on X (Twitter), Facebook , LinkedIn , and Instagram . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development of ANKTIVA® (nogapendekin alfa inbakicept-pmln), the potential benefits of ANKTIVA-based immunotherapy in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC), future regulatory submissions and approvals, commercialization plans and market potential, and the company's strategic vision for restoring immune competence in cancer patients. These forward-looking statements are based on ImmunityBio's current expectations and beliefs and are subject to uncertainties and factors that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to: the risk that clinical trials may not demonstrate adequate safety and efficacy to support regulatory approval or may be delayed or terminated; the risk that regulatory authorities may not approve ANKTIVA for additional indications or may impose restrictions on its use; the risk that the company may not successfully commercialize ANKTIVA or achieve market acceptance; competition from other therapies; manufacturing and supply chain risks; intellectual property risks; and the company's ability to obtain additional funding to support its operations. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2026 as well as its Form 10-Q filed with the SEC on May 7, 2026, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at . ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 858-746-9289 Hemanth.Ramaprakash@ImmunityBio.com Media Sarah Singleton ImmunityBio, Inc. +1 415-290-8045 Sarah.Singleton@ImmunityBio.com

100 Deals associated with Tislelizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11487	Tislelizumab	L01XC	DB14922

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Esophageal Carcinoma	Japan	BeOne Medicines Ltd.	27 Mar 2025
PD-L1 positive Esophageal Squamous Cell Carcinoma	United States	BeOne Medicines USA, Inc.	03 Mar 2025
Locally Advanced Gastric Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastric Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Locally Advanced Gastroesophageal Junction Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Metastatic gastric adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	European Union	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Iceland	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Liechtenstein	BeOne Medicines Ltd.	19 Dec 2024
Metastatic Gastroesophageal Junction Adenocarcinoma	Norway	BeOne Medicines Ltd.	19 Dec 2024
Resectable Lung Non-Small Cell Carcinoma	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	16 Oct 2024
Extensive stage Small Cell Lung Cancer	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	25 Jun 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2 Positive Adenocarcinoma of Esophagus	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2 positive Gastrooesophageal junction cancer	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2-positive gastric cancer	NDA/BLA	United States	BeOne Medicines Ltd.	29 Apr 2026
HER2 Positive Stomach Adenocarcinoma	NDA/BLA	China	Boehringer Ingelheim Biopharmaceuticals (China) Ltd.	14 Apr 2026
HER2 Positive Stomach Adenocarcinoma	NDA/BLA	China	BeiGene Guangzhou Biologics Manufacturing Co. Ltd.	14 Apr 2026
stomach adenocarcinoma	NDA/BLA	European Union	BeOne Medicines Ireland Ltd.	17 Oct 2024
Squamous Cell Carcinoma	NDA/BLA	China	BeOne Medicines Ltd.	06 Sep 2018
Advanced Gastroesophageal Junction Adenocarcinoma	Phase 3	China	RemeGen Co., Ltd.	01 Jan 2026
HER2-expressing Gastroesophageal Junction Adenocarcinoma	Phase 3	China	RemeGen Co., Ltd.	01 Jan 2026
Colorectal Cancer	Phase 3	France	BeOne Medicines Ltd.	16 Apr 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05609370 (CTgov)	Phase 1/2	Metastatic Microsatellite Stable Colorectal Carcinoma \| Metastatic Colorectal Carcinoma	113	Tislelizumab+Bevacizumab+Alcestobart+Fluoropyrimidine (FP) (Phase 1b: Alcestobart Low Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine)	ccwouwgokj = howcfeuhjz sfnmayjnob (jiniaokkzy, khwhbnxusx - bvjsrwbssk) View more	-	30 Jun 2026
NCT05609370 (CTgov)	Phase 1/2		113	Tislelizumab+Bevacizumab+Alcestobart+Fluoropyrimidine (FP) (Phase 1b: Alcestobart Medium Dose + Tislelizumab + Bevacizumab + Fluoropyrimidine)	ccwouwgokj = btztlngoah sfnmayjnob (jiniaokkzy, ovdcgivayo - xjrjefrqta) View more	-	30 Jun 2026
Pubmed \| Clin Cancer Res	Phase 2	Pulmonary sarcomatoid carcinoma First line	29	Tislelizumab plus Anlotinib	pculfeydju(bnxifinmaz) = fktoxaeosv qkampvwzab (usbdcmqdbu, 35.69 - 73.55) View more	Positive	15 Jun 2026
NCT03594747 (RATIONALE-307, Pubmed \| Oncol Ther)	Phase 3	Squamous non-small cell lung cancer First line	665	Tislelizumab plus paclitaxel/carboplatin	kvyqvlbzgs(zlmyqhizpg) = rtmazrcayv btykztjokv (eijgmzhmun, 6.7 - 9.9) View more	Positive	01 Jun 2026
NCT03594747 (RATIONALE-307, Pubmed \| Oncol Ther)	Phase 3	Squamous non-small cell lung cancer First line	665	Tislelizumab plus nab-paclitaxel/carboplatin	kvyqvlbzgs(zlmyqhizpg) = iukzrkwyqd btykztjokv (eijgmzhmun, 7.4 - 10.1) View more	Positive	01 Jun 2026
NCT05520619 (EC-CRT-002, Pubmed \| J Clin Oncol)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	114	Tislelizumab + Induction Chemotherapy + Concurrent Chemoradiotherapy	kljmunkhwi(qtxweomjcj): HR = 0.54 (95.0% CI, 0.32 - 0.94) View more	Positive	01 Jun 2026
NCT05520619 (EC-CRT-002, Pubmed \| J Clin Oncol)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma	114	Tislelizumab + Induction Chemotherapy + Concurrent Chemoradiotherapy		Positive	01 Jun 2026
NCT05542342 (GEM-2101 \| SITISVEAL, CTgov)	Phase 2	Uveal Melanoma \| Liver metastases \| Metastatic melanoma	16	Tislelizumab+Sitravatinib	rbxvcknlii = pnltqqsyrv ddxdayfvus (mjclisvcsi, ftzslvjhdh - fhdsbqmkip) View more	-	01 Jun 2026
IKF-080 (ASCO2026)	Phase 2	MSS/pMMR/MSI-L Colorectal Carcinoma microsatellite-stable	140	Fruquintinib 5 mgTislelizumab 400 mg + Fruquintinib 5 mgTislelizumab 400 mg (Metastatic colorectal adenocarcinoma + No active liver metastases)	eqekktskyq(mvswyklyzd) = oveqmblftq smswdflnry (ngvhtliwac, 16 - 33)	Positive	29 May 2026
IKF-080 (ASCO2026)	Phase 2	MSS/pMMR/MSI-L Colorectal Carcinoma microsatellite-stable	140	Bevacizumab 5 mg/kgcil 35 mg/m² + Bevacizumab 5 mg/kg (Metastatic colorectal adenocarcinoma + No active liver metastases)	eqekktskyq(mvswyklyzd) = eowxajmpom smswdflnry (ngvhtliwac, 3 - 10) View more	Positive	29 May 2026
ASCO2026	Not Applicable	Transitional Cell Carcinoma Neoadjuvant	10	Tislelizumab+cisplatin+gemcitabine + Tislelizumabcisplatingemcitabine (clinically node-positive urothelial carcinoma)	cavoyuqihu(drjynepehy) = iewkijfmaa gikptdnwog (lgbhjvnnce ) View more	Positive	29 May 2026
NCT06451211 (PERISCOPE-01, ASCO2026)	Phase 2	Stomach Cancer Neoadjuvant pMMR	56	Tislelizumab + platinum-based chemotherapy	mcbylylthv(uyemmbrhrs) = dkceukdpgx oxajqeljsn (qbopvrtlgc, 21 - 48) View more	Positive	29 May 2026
NCT06124378 (ASCO2026)	Phase 2	Colonic Cancer Neoadjuvant microsatellite stable/mismatch repair proficient (MSS/pMMR)	61	Tislelizumab plus CAPOX	wudzlroqrs(kjqdrclpte) = vbyyxhztwy gdezlmhawv (zdntewvbut ) View more	Positive	29 May 2026
NCT05253118 (SPECTRUM, ASCO2026)	Phase 2	Diffuse Large B-Cell Lymphoma	29	TislelizumabPemetrexedab + TislelizumabPemetrexed	jcrnleeqzq(sdvxdhbkpv) = vgdnxhymqs askiobcuur (ubeydmnklf ) View more	Positive	29 May 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Tislelizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation